MANDATE / 2016 — PRESENT
Early-stage therapeutics.Oncology · Immunology · Urology.
$400M AUM. Preclinical through proof of concept. Co-invests alongside top-tier institutional life-science syndicates. Strategic access to Asian markets through Taiho Pharmaceutical.
AUM · FUND I + II
$400M
▲ +$80M YTDPORTFOLIO COMPANIES · ACTIVE
27
▲ +3 LTMIPO + M&A · 2016 — 2026
6
▲ +1 LTMACTIVE SYNDICATES
12
· STABLEFILTER
THERAPEUTIC AREA3/3
- Oncology52%
- Immunology31%
- Urology17%
STAGE3/4
- Preclinical40%
- Phase 135%
- Phase 2 / POC25%
- Phase 3opportunistic
MODALITY3/5
- Small molecule
- Biologics
- ADC
- Cell & gene therapy
- Targeted protein degrader
GEOGRAPHY1/3
- North Americaprimary
- Europeselective
- Japan / Asia bridgestrategic
PORTFOLIO · WATCHLIST9 of 27 · sorted by trail momentum
OPEN FULL WATCHLIST →TICKERCOMPANYTHERAPYPHASEMODALITYLAST ROUND12M TRAILUPD
- LEADKAIR-045Kairos OncIPO ▲IPO ▲Oncology·IPO14h
- PYRA-031Pyranex TxPH3PH3Oncology·$120M · D02d
- LEADARCH-024Archimer BioPH2PH2Oncology·$80M · C06h
- CTRL-022CytrolinePH2PH2Immunology·$55M · B11h
- LEADIMNX-012Immnex TxPH1PH1Immunology·$42M · B03d
- VECT-067Vectris BioPH1PH1Oncology·$30M · A01d
- NCT-401Noctar TxPH1PH1Immunology·$24M · A04d
- LEADRENL-008RenluxPRECLINPRECLINUrology·$18M · Seed08h
- TIO-118Tioga BioPRECLINPRECLINUrology·$12M · Seed12d
PARTNERCO-DEALSOVERLAPLAST DEAL
- ARCH Venture Partners8ARCH-024 · 2026-02
- GV5IMNX-012 · 2025-11
- MPM BioImpact6KAIR-045 · 2025-04
- 5AM Ventures4PYRA-031 · 2025-08
- Third Rock3CTRL-022 · 2025-09
- SR One5NCT-401 · 2025-10
- Mubadala (Asia bridge)2TIO-118 · 2025-07